{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:21:31Z","timestamp":1767180091978,"version":"build-2238731810"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0201956","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:35:14Z","timestamp":1534426514000},"page":"e0201956","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Infliximab for pediatric patients with Crohn\u2019s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan"],"prefix":"10.1371","volume":"13","author":[{"given":"Hitoshi","family":"Tajiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukunori","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Maemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieko","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Susuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/gut.42.3.309","article-title":"Inflammatory bowel disease incidence: up, down or unchanged?","volume":"42","author":"RF Logan","year":"1998","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"NA Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"ref3","first-page":"33","article-title":"Inflammatory bowel disease: an expanding global health problem","volume":"6","author":"AE M\u2019Koma","year":"2013","journal-title":"Clin Med Insights Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1111\/j.1572-0241.2008.02158.x","article-title":"An update on the epidemiology of inflammatory bowel disease in Asia","volume":"103","author":"KT Thia","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00535-010-0223-7","article-title":"Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan","volume":"45","author":"T Ishige","year":"2010","journal-title":"J Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bpg.2014.04.003","article-title":"Epidemiology of inflammatory bowel disease: focus on Asia","volume":"28","author":"SC Ng","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"EI Benchimol","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1359\/jbmr.040908","article-title":"Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition","volume":"19","author":"JM Burnham","year":"2004","journal-title":"J Bone Miner Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.cgh.2008.07.010","article-title":"Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn\u2019s disease: results of the REACH study","volume":"6","author":"M Thayu","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpeds.2013.02.010","article-title":"Delays in puberty, growth, and accrual of bone mineral density in pediatric Crohn\u2019s disease: despite temporal changes in disease severity, the need for monitoring remains","volume":"163","author":"MD DeBoer","year":"2013","journal-title":"J Pediatr"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn\u2019s disease","volume":"16","author":"RD Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn\u2019s disease","volume":"8","author":"FM Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ibd.20378","article-title":"Guidelines for the management of growth failure in childhood inflammatory bowel disease","volume":"14","author":"R Heuschkel","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"ref14","first-page":"30","article-title":"Guidelines for the management of pediatric Crohn\u2019s disease","volume":"117","author":"H Tajiri","year":"2013","journal-title":"Jpn Pediatr Soc"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"SB Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"J Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn\u2019s disease","volume":"18","author":"T Hibi","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00005176-199105000-00005","article-title":"Development and validation of a pediatric Crohn\u2019s disease activity index","volume":"12","author":"JS Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"RN Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70173-3","article-title":"Assessing activity of pediatric Crohn\u2019s disease: which index to use?","volume":"116","author":"A Otley","year":"1999","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1097\/MIB.0000000000000475","article-title":"Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn\u2019s Disease: A Prospective Clinical Trial","volume":"21","author":"Y Suzuki","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ibd.22902","article-title":"Doubling the infliximab dose versus halving the infusion intervals in Crohn\u2019s disease patients with loss of response","volume":"18","author":"L Katz","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn\u2019s disease at a pediatric inflammatory bowel disease center","volume":"98","author":"MC Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"EA Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5009\/gnl16041","article-title":"Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease","volume":"11","author":"SY Choi","year":"2017","journal-title":"Gut Liver"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"28272355","DOI":"10.3390\/ijms18030575","article-title":"Serum-infliximab trough levels in 45 children with inflammatory bowel disease on maintenance treatment","volume":"18","author":"H Rolandsdotter","year":"2017","journal-title":"Int J Mol Sci"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0261932","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0201956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T20:18:24Z","timestamp":1589919504000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0201956"}},"subtitle":[],"editor":[{"given":"Emiko","family":"Mizoguchi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0201956","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}